Araclon Biotech Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
22
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$10.9M
Araclon Biotech General Information
Description
Operator of a biotechnology company intended for the research and development of therapies and methods for the diagnosis of degenerative diseases. The company is primarily engaged in the development of tests for the analysis of β-amyloid peptides in human plasma, a precursor for diagnosing Alzheimer's disease and also developing immunotherapy vaccines for tackling those β-amyloid peptides, enabling physicians to prevent the disease or delay the onset of symptoms.
Contact Information
Website
www.araclon.com(Operating Subsidiary)
Corporate Office
- Vía Hispanidad, 21
- 50009 Zaragoza
- Spain
Corporate Office
- Vía Hispanidad, 21
- 50009 Zaragoza
- Spain
Araclon Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 29-Feb-2012 | $10.9M | Completed | Generating Revenue | ||
| 2. IBO | 15-Feb-2012 | Completed | Generating Revenue | |||
| 1. Early Stage VC | Completed | Generating Revenue |
Araclon Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Araclon Biotech Patents
Araclon Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021262526-A1 | Methods for quantification of amyloid beta peptides in plasma by mass spectrometry | Pending | 29-Apr-2020 | ||
| CA-3175681-A1 | Methods for quantification of amyloid beta peptides in plasma by mass spectrometry | Pending | 29-Apr-2020 | ||
| EP-4145134-A1 | Methods for quantification of amyloid beta peptides in plasma by mass spectrometry | Pending | 29-Apr-2020 | ||
| US-20230258651-A1 | Methods for quantification of amyloid beta peptides in plasma by mass spectrometry | Pending | 29-Apr-2020 | ||
| ES-2571055-B1 | Amyloid conjugate and its uses and procedures | Active | 15-Feb-2016 | A61K38/1767 |
Araclon Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Araclon Biotech Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Going Investment | PE/Buyout | Minority | ||
| Mobius Venture Capital | Venture Capital | Minority | ||
| VIA Technologies | Corporation | Minority |
Araclon Biotech FAQs
-
When was Araclon Biotech founded?
Araclon Biotech was founded in 2004.
-
Where is Araclon Biotech headquartered?
Araclon Biotech is headquartered in Zaragoza, Spain.
-
What is the size of Araclon Biotech?
Araclon Biotech has 22 total employees.
-
What industry is Araclon Biotech in?
Araclon Biotech’s primary industry is Drug Discovery.
-
Is Araclon Biotech a private or public company?
Araclon Biotech is a Private company.
-
What is the current valuation of Araclon Biotech?
The current valuation of Araclon Biotech is .
-
What is Araclon Biotech’s current revenue?
The current revenue for Araclon Biotech is .
-
Who are Araclon Biotech’s investors?
Going Investment, Mobius Venture Capital, and VIA Technologies have invested in Araclon Biotech.
-
When was Araclon Biotech acquired?
Araclon Biotech was acquired on 29-Feb-2012.
-
Who acquired Araclon Biotech?
Araclon Biotech was acquired by Grifols.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
